Cognition Q3 Loss Narrows to $4.1M; Cash Runs Into Q4 2027 as Nasdaq Deficiency Looms
CGTX sits 24% above its 52-week low of $0.55.
Summary
Cognition Therapeutics posted a narrower $4.1M Q3 loss with $31.5M in cash and runway into Q4 2027, while disclosing a Nasdaq minimum-bid deficiency that must be cured by May 3, 2027.
Key Events · Earnings and Guidance · CGTX
-
Q3 Loss Narrows to $4.1M
Net loss for the quarter ended September 30, 2026 was $4.145M, or $0.04 per share, versus $4.930M a year earlier. Nine-month loss fell to $12.647M from $20.144M.
-
Cash of $31.5M, Runway Into Q4 2027
Cash, cash equivalents and restricted cash totaled $31.475M at September 30, 2026. Management says this funds operations into Q4 2027 assuming no usage from the 2025 ATM.
-
Nasdaq Minimum-Bid Deficiency
Nasdaq notified the company on November 3, 2026 that its bid had been below $1.00 for 30 consecutive business days. It has until May 3, 2027 to close at $1.00 or higher for 10 straight days, with a reverse split the stated option.
-
ATM Leaves $68.0M of Headroom
The company sold 5,550,659 shares under the 2025 ATM in the first nine months of 2026 for gross proceeds of about $7.0M; $68.0M remains available for future issuance.
Analysis · CGTX · Life Sciences
The quarter itself is an improvement: the net loss fell to $4.1M from $4.9M a year ago, and nine-month R&D dropped to $16.3M from $26.0M as trial activity slowed. With $31.5M of cash and equivalents, management says funding lasts into Q4 2027 without touching the $68.0M still available under the 2025 ATM — but that runway depends on continued NIA grant reimbursements and does not fund a Phase 3 program. Against that backdrop, the stock closed below $1.00 for 30 straight business days, and Nasdaq gave the company until May 3, 2027 to cure, with a reverse split the stated fallback. The clinical story is intact — FDA agreed in October on the DLB registrational design — but the balance sheet and the listing clock are now the binding constraints.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CGTX was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $65M. The 52-week trading range was $0.55 to $1.83. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.